Sanofi’s plans for rilzabrutinib continue apace with positive mid-stage data in IgG4-related disease ahead of a potential US approval in the summer for the potential ‘pipeline-in-a-product’ in immune thrombocytopenia (ITP).
Key Takeaways
- Treatment with rilzabrutinib led to a considerable reduction in disease flares in patients with active IgG4-related disease.
The French drugmaker has presented new data at the European Alliance of Associations for Rheumatology (EULAR) congress in Barcelona, Spain,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?